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ABSTRACT 
LIG proteins are distinguished by their Leucine-rich repeats (LRRs) and immunoglobulin 
(Ig)-like domains, present in the proteins’ extracellular regions. The Drosophila LIG protein 
Kekkon1 is known for its inhibitory effect on the Drosophila epidermal growth factor receptor. 
Some members of the LIG protein superfamily have been shown to enhance or inhibit cell 
survival, growth, and differentiation in the Central Nervous System (CNS), but little is known 
about the majority of family members. To shed light on the still nonclarified functions of LIG 
proteins, this project focuses on identifying specific homophilic and heterophilic interactions 
between a subset of LIG family proteins and ErbB growth factor receptors.   
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INTRODUCTION 
The Central Nervous System is a mansion of scientific secrets. Centuries of extensive 
research and technological innovations have produced a wealth of knowledge in the anatomy and 
physiology of humans and numerous model organisms. Yet, the intricate developmental and 
operational mechanisms of the nervous system are still largely undeciphered. Cellular signaling 
plays a key role in the formation and function of the brain, the spinal cord, and all nerves. 
Therefore, understanding intercellular communication will shed light on the processes that 
govern the nervous system. To provide insight into the neuronal functions of a subset of human 
LIG family proteins, this project sought to investigate the homophilic and heterophilic 
interactions between members of this transmembrane family and the four ErbB growth factor 
receptors, by means of a high-throughput ELISA assay. 
The Epidermal Growth Factor Receptor (EGFR) Family and Cell Signaling 
The Epidermal Growth Factor Receptor (EGFR, ErbB1), as well as ErbB2, ErbB3, and 
ErbB4 make up the ErbB family of growth factor receptor tyrosine kinases (RTK). The general 
structure of the ErbB glycoproteins, illustrated in Figure 1, includes an extracellular region 
composed of four domains, a single transmembrane region, and a tyrosine kinase domain in the 
intracellular C terminus. Domains I and III are the leucine-rich sites of ligand binding, while 
domains II and IV are cysteine-rich and form the dimerization interface during ErbB activation. 
(Burgess AW, 2003)  
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Figure 1: Molecular Structure of ErbB family proteins. (Burgess AW, 2003) 
Figure 2 depicts the structural features of the four human ErbB transmembrane proteins 
and of the Drosophila EGFR (dEGFR) version. dEGFR bears structural similarity to ErbB2, 
except for the presence of a fifth cysteine-rich domain in the extracellular region of dEGFR. 
Unique among the receptors is ErbB2 which is an orphan receptor with no known ligand, and 
ErbB3 which does bind ligand, but has an inactive intracellular kinase region.  
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Figure 2: Molecular structures of dEGFR and the ErbB protein family.  
The ErbB mechanism of receptor-mediated activation, presented in Figure 3, consists of 
homo- or hetero-dimerization of ErbB1, ErbB2, ErbB3 or ErbB4, induced by binding of ligands 
such as EGF. (Burgess AW, 2003) While domains I and III interact with the ligand, domains II 
and IV interact between the two dimerization partners. (Burgess AW, 2003) As a result, specific 
tyrosine residues in the receptor’s Carboxy (C) terminus get autophosphorylated and activate 
RTK signaling pathways, which regulate a variety of processes critical for cell proliferation, 
differentiation, and migration. For instance, activation of EGFR triggers the 
Ras/Raf/MEK/MAPK signaling cassette, eventually resulting in changes in the transcriptional 
profile of the cell. (Ghiglione G. C., 1999) 
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Figure 3: Mechanism of ErbB activation.  
Constitutive activation of ErbB receptors is associated with uncontrolled cell growth and 
tumor development. ErbB2 is the only protein of the family that does not require a ligand in 
order to dimerize and trigger RTK signaling cascades. As a result, elevated ErbB2 activity is 
observed in cases of advanced breast cancer, as well as some ovarian, gastric, and salivary 
cancers. (Burgess AW, 2003) Cancer therapy will benefit from molecules that interfere with 
receptor activation, such as the ErbB2-targeted Herceptin antibody used in breast cancer 
treatment. (Ghiglione C. A., 2003) 
Regulation of dEGFR by the LIG family member Kekkon1 
Kekkon1 (Kek1), a member of the Drosophila LIG protein family, consists of a molecule 
with a single transmembrane region and extracellular domains, including seven leucine-rich 
repeats (LRR) and one Immunoglobulin-like (Ig) domain participating in cell adhesion. 
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(Ghiglione G. C., 1999) Leucine-rich repeats typically consist of 20 to 29 amino acids ordered in 
a β-strand and an α-helix which are connected by loops and form a curved structure. LRR motifs 
include the conserved sequence of LxxLxLxxN/CxL, where L can be substituted for V, I, or F 
and x is any amino acid. 
Studies have revealed an inhibitory function of Kek1, since knockout of the protein has 
been associated with enhanced signaling of dEGFR, which is structurally similar to ErbB2. 
(Alvarado D K. D., 2009) Conversely, Kek1 misexpression results in phenotypes similar to 
diminished dEGFR function, such as the extreme ventralization observed in chorions (eggshells) 
mutant for dEGFR. A direct proportionality has been demonstrated between Kek1 and EGFR 
expression, where EGFR hyperactivation causes enhanced Kek1 expression; the opposite case 
has also been observed. (Ghiglione G. C., 1999) 
The process of inhibition, depicted in Figure 4, involves direct binding of the 
extracellular LRR domains and transmembrane regions of Kek1 and the EGFR. (Alvarado D R. 
A., 2004) Proposed mechanisms suggest that Kek1 may hinder ligand access to EGFR and block 
EGFR dimerization. By preventing EGFR activation, Kek1 functions as a regulator of the RTK 
signaling cascade in a negative feedback loop. (Ghiglione G. C., 1999) 
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Figure 4: EGFR Inhibition by Kekkon1.  
 
LIG Protein Superfamily 
The human LIG family (presented in Figure 5) includes a total of 36 proteins: three 
AMIGO, two Adlican, two GPR, two ISLR, four LINGO, three LRIG, three NGL, three NLRR, 
three Pal, two Peroxidasin-like proteins, five SALM, three Trk neurotrophin receptors, and the 
unnamed AAI11068. (Homma S, 2009) LIG family members are transmembrane proteins which 
contain both various numbers of LRR and Ig-like domains in their extracellular regions. The 
molecular structure of representatives from a few main LIG protein subfamilies is illustrated in 
Figure 6. Human LIG proteins are expressed in a variety of tissues and their exact functions are 
still largely undefined. However, many of them are suspected to play roles in the CNS.  
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Figure 5: Human LIG Protein Structures. (Homma S, 2009) 
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Figure 6: Molecular structures of proteins from some main LIG subfamilies.  
Amphoterin-Induced Gene and ORF (AMIGO), AMIGO-2 and AMIGO-3 constitute a 
family of type I transmembrane proteins characterized by six LRR motifs and one Ig-like 
domain, as depicted in Figure 7. The AMIGO gene is predominantly expressed in the nervous 
system, particularly in the fibers and tracts of axons in the brain. The gene’s ectodomain has 
been shown to enhance neurite extension and prevent neurite fasciculation of hippocampal 
neurons in culture. The timeframe of AMIGO up-regulation also indicates that the protein may 
modulate axonal myelination. AMIGO levels are high until the end of adolescence; therefore the 
protein may be important for regeneration and flexibility of adult neurons. (Kuja-Panula, 2003) 
AMIGO-2 and AMIGO-3 are expressed not only in the brain, but also in other organs. In 
particular, AMIGO-2, also named alivin-1, has been shown to promote the depolarization-
dependent survival of cerebellar granule neurons. The protein may have a similar effect in its 
other expression sites, such as the dentate gyrus granule cells and hippocampal neurons. (Kuja-
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Panula, 2003) AMIGO-2 expression has also been associated with gastric adenocarcinoma 
(GEDA) cases, where it is detected in about 45% of tumor masses as opposed to healthy tissue. 
These findings indicate that AMIGO-2 may be involved in cancer cell survival. 
 
Figure 7: Schematic Structure of AMIGO proteins. (Kuja-Panula, 2003) 
LINGO-1 is the main member of the LRR and Ig domain containing Nogo receptor 
interacting protein family. It is a type I transmembrane protein containing 12 LRR motifs and a 
single Ig-like domain. The protein is most abundantly expressed among a group of four 
homologues, LINGO-1 through 4. LINGO-1 has a tyrosine phosphorylation site on its 
cytoplasmic terminus, although it has not been confirmed that phosphorylation occurs. LINGO-1 
associates with the NgR protein, thus facilitating NgR/p75 NTR signaling in non-neuronal cells. 
(Chen Y. A., 2006) Expression of LINGO-1 is likely controlled by neuronal activity and occurs 
predominantly in the brain, but also in the neocortex and the limbic system. Consistent with its 
function in NgR/p75 NTR signaling, LINGO-1 overexpression is correlated with increased 
sensitivity to myelin-associated inhibitors of neurite extension. (Chen Y. A., 2006) LINGO-1 
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also negatively regulates differentiation and myelination of oligodendrocytes: LINGO-1 
knockout leads to better myelinated axon fibers and more mature oligodendrocytes in newborn 
mice. (Chen Y. A., 2006) In relation to the function of LINGO-1 in neuronal outgrowth 
inhibition, some studies have associated a specific variant of the gene with both the Essential 
tremor and Parkinson’s disease, but this remains to be confirmed. (Deng, 2012)  
The Leucine-Rich Repeats and Immunoglobulin-like domains (LRIG) protein family 
consists of three members, LRIG 1 through 3, which have 15 LRR motifs and three Ig-like 
domains. The LRR motifs of LRIG1 are homologous to those of Kek1 and have been shown to 
inhibit EGFR activity and growth in carcinoma cells. LRIG1 is often poorly expressed in 
different tumor types, since its gene region is often deleted in many cancer cases. (Goldoni, 
2007) On the contrary, LRIG 2 inhibition has been correlated with loss of EGFR activation and 
decreased growth in glioma cells. (Alsina, 2012) 
Netrin-G Ligand-1 (NGL-1) contains 9 LRR motifs and one Ig-like domain. Through its 
LRR region, NGL-1 acts as a ligand to the highly conserved netrin G1, which guides axonal 
elongation and migration for a variety of neuronal cell types. NGL-1 is expressed in the brain 
and is most ubiquitous in the striatum and the cerebral cortex. When bound to netrin G1, NGL-1 
has been shown to promote the in vitro elongation of embryonic thalamic neurons. (Chen Y. A., 
2006) 
The first three members of the Neuronal Leucine-Rich Repeat (NLRR) protein family 
have 11 to 12 LRR motifs, one Ig-like domain, and one fibronectin type III (FN-III) domain. All 
three NLRR are largely expressed in the brain, but at different locations. Their exact functions in 
the CNS have not been fully elucidated. NLRR-2 has been up-regulated in malignant gliomas, 
while NLRR-3 gets overexpressed after cortical injury. NLRR-3 is activated by the epidermal 
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growth factor and participates in the Ras-MAP kinase (MAPK) signaling pathway. The lack of 
NLRR-4, which does not contain an Ig-like domain, has been shown to result in impaired 
hippocampal-dependent memory retention. (Chen Y. A., 2006) 
The photoreceptor-associated LRR superfamily gene (PAL) includes five LRR motifs, 
one C2-type Ig-like domain and one FN-III domain. PAL is specifically expressed in the retina 
and is associated with the development of the outer segments of photoreceptors. (Chen Y. A., 
2006) 
 Potential LIG Protein Functions 
Cellular Receptors 
LINGO-1 has exhibited receptor functions as a component of the NgR1/p75/LINGO-1 
and the NgR1/TAJ (TROY)/LINGO-1 signaling pathways that inhibit axonal outgrowth. Nogo-
A, myelin-associated glycoprotein (MAG), oligodendrocyte-myelin glycoprotein (OMgp), and 
ephrin-B3 are myelin sheath inhibitory components that bind the NgR1 receptor. (Ji, 2006) The 
NgR1 receptor associates with the Ig-like domain of LINGO-1, triggering the mentioned 
signaling pathways. More specifically, the EGF receptor-like tyrosine phosphorylation site of 
LINGO-1 is considered as the connecting component between the ligand-binding NgR1 and the 
signal-transducing p75 or TAJ (TROY). (Satoh, 2007)  LINGO-1 overexpression activates the 
intracellular cytoskeleton regulator RhoA, which in turn disables axonal elongation and 
regeneration, as depicted in Figure 8. (Ji, 2006) LINGO-1 inhibition has resulted in improved 
neuron and oligodendrocyte survival, as well as regeneration, differentiation, and overall 
recovery after cell injury. These findings have identified LINGO-1 as an important target for 
neurotherapeutic agents. (Mi, 2008)  
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Figure 8: LINGO-1 Signaling Complexes and Pathways. (Mi, 2008)  
Cell Adhesion Molecules 
In general, Ig-like domains have been identified as the components responsible for cell 
adhesion interactions. For instance, the neuronal cell adhesion molecule (NCAM), which is a 
member of the Ig superfamily, is a factor controlling the shape, proliferation and migration of 
neurons and affecting their plasticity in adult organisms. The Ig domains of LIG proteins are 
considered as protein interaction sites, however their exact function as cell adhesion domains in 
the CNS has not yet been determined. (Chen Y. H., 2012) 
AMIGO proteins have been shown to participate in both homophilic and heterophilic 
binding. Hence, cell adhesion has been proposed as a potential function for the AMIGO protein 
family, aimed at promoting neuronal growth. (Kuja-Panula, 2003) Unlike the AMIGO protein 
family, no homophilic or heterophilic trans-cell interactions has been demonstrated between 
LINGO-1 molecules yet.  
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MATERIALS AND METHODS 
Generation of LIG Constructs through the Gateway Cloning System 
The Gateway cloning system utilizes the site-specific recombination features of 
bacteriophage lambda. (Invitrogen Corporation, 2010) The system allows the introduction of 
specific DNA sequences into a variety of vector types. Recombination events occur at specific 
DNA regions called att sites. Gateway cloning involves two types of recombination reactions, 
BP and LR. In a BP reaction, an attB site-flanked gene of interest is inserted into a donor vector 
containing an attP site-flanked ccdB gene toxic to E.coli, which eliminates the expression of by-
product constructs. As illustrated in Figure 9, the BP reaction results in an entry clone that 
includes the gene of interest flanked by attL sites. The LR reaction involves the recombination of 
the entry clone (attL sites) with a destination vector carrying a tag gene and an attR site-flanked 
ccdB gene. Thus, the main product of the LR reaction is an expression clone containing both the 
attB site-flanked gene of interest and the tag gene (Figure 10). Due to the presence of attB sites, 
an expression clone can be used in a BP reaction to yield an entry clone with the gene of interest. 
Entry clones carry kanamycin resistance, while expression clones are resistant to ampicillin, 
allowing for the selection of desired constructs.  
 
Figure 9: BR reaction mechanism. (Invitrogen Corporation, 2010) 
 
DNA primers designed in the Duffy lab were used to PCR-amplify only the extracellular 
regions of the Amigo 1, Amigo 3, Lingo 1, and LRIG 1 genes. A BP reaction was performed, 
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inserting the PCR products into the pDONR 221 vector, resulting in pENTR entry clones. A BP 
reaction was also made with a pUAST sAmigo 2 – 6xHis/V5 expression clone, previously 
produced in the Duffy lab. Figure 9 displays the mechanism of the BP reaction that produced 
pENTR sAmigo 1. The BP reaction mixtures were prepared as follows: 75ng PCR product (or 
expression clone) in up to 3μl, 75ng pDONR 221 in 1μl, and 1μl BP clonase enzyme mix from 
Invitrogen, mixed well and incubated at 25°C overnight. 1μl Proteinase K was added to each 
reaction, followed by a 10-minute incubation at 37°C. 1μl of each BP reaction was transformed 
into 50μl of Max Efficiency DH5α competent cells from Invitrogen; 60% of each transformation 
was plated on 50μg/ml kanamycin LB agar plates incubated overnight at 37°C. Selected colonies 
of each transformed reaction were inoculated in 5ml LB containing 50μg/ml kanamycin and 
grown overnight at 37°C. Liquid cultures were miniprepped with the Qiaprep Spin Miniprep Kit 
from Qiagen. The pENTR sAmigo 1, pENTR sAmigo 2, and pENTR sAmigo 3 clones were 
sequenced by Eton Bioscience (Boston, MA) and the results were evaluated with Sequencher 
software. A Nanodrop spectrophotometer was used to measure the DNA concentrations of the 
samples.  
 
Figure 10: LR reaction mechanism. (Invitrogen Corporation, 2010) 
The generated pENTR entry clones were inserted into three types of vectors through LR 
reactions. The used vectors were pUAST 6xHis/V5, pUAST GFP, and pUAST AP (alkaline 
phosphatase). Figure 10 displays the mechanism of the LR reaction that produced pUAST 
sAmigo 1 - AP. The LR reaction mixtures were prepared as follows: 75ng pENTR clone in up to 
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3μl, 75ng pUAST clone in 1μl, and 1μl LR clonase enzyme mix from Invitrogen, mixed well and 
incubated at 25°C overnight. 1μl Proteinase K was added to each reaction, followed by a 10-
minute incubation at 37°C. 1μl of each LR reaction was transformed into 50μl of high efficiency 
5-alpha competent E. coli cells from NEB; 60% of each transformation was plated on 50μg/ml 
ampicillin LB agar plates incubated overnight at 37°C. Selected colonies of each transformed 
reaction were inoculated in 5ml LB containing 50μg/ml ampicillin and grown overnight at 37°C. 
Liquid cultures were miniprepped with the Qiaprep Spin Miniprep Kit from Qiagen. A Nanodrop 
spectrophotometer was used to measure the DNA concentrations of the samples.  
 
Co-transfection of LIG Expression Clones with Arm-GAL4 
An S3 Drosophila cell line was maintained on Schneider’s media containing 12.5% FBS. 
5x10
6
 cells per well in a total of 2.5ml were seeded in 6-well plates and incubated at 25°C until 
100% confluence was reached. Each well was co-transfected with 400ng of expression clone 
construct (pUAST sAmigo 1 – 6xHis/V5, pUAST sAmigo 2 – 6xHis/V5, pUAST sAmigo 3 – 
6xHis/V5, pUAST sKek 1– 6xHis/V5, pUAST sKek 2 – 6xHis/V5, pUAST sLingo 1 – 
6xHis/V5, and pUAST sLRIG 1 – 6xHis/V5) and 400ng of Arm-GAL4 driver construct, 
following the Qiagen Transfection Kit protocol. Figure 11 depicts the mechanism of construct 
expression through the UAS-GAL4 system. In co-transfected cells, GAL4 gets expressed first 
and acts as a transcriptional activator for the expression of the tagged construct of interest. After 
an 1-week incubation at 25°C, supernatants were collected from each co-transfection well, 
sterilized through a 0.2 micron Whatman syringe filter, and stored in 1.5ml Eppendorf tubes at 
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4°C. 
 
Figure 11: UAS-GAL4 expression system.  
 
Western Blotting of LIG Protein Supernatants 
Protein supernatants, including a negative control, were run on 8% SDS-PAGE gels 
following the common protocol used in the Duffy lab. Samples were transferred from the gels 
onto nitrocellulose membranes, probed with monoclonal mouse anti-6xHis/V5 antibody from 
Invitrogen diluted 1:5,000 in 5% NFDM TBST solution. Goat anti-mouse HRP-conjugated 
antibody from Jackson ImmunoResearch diluted 1:20,000 in 5% NFDM TBST was used as a 
secondary antibody. Using the ECL chemiluminescent substrate reagent kit from Invitrogen, 
probed membranes were incubated with 1:1 of luminol and enhancer solution and pictures were 
developed using an X-Omat machine and Kodak film.  
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ELISA Assay for Evaluation of LIG Protein Concentration 
200μl of 6xHis/V5-tagged supernatants and negative control supernatant at 1:10, 1:20, 
1:40, 1:200, and 1:400 dilutions in PBS/BSA were added into the wells of a 96-well Qiagen Ni-
NTA HisSorb Plate and incubated for 1 hour at room temperature with nutation. Each well was 
washed 4 times with 250μl PBS-Tween, 1 minute per wash. Wells were dried and incubated with 
200μl of monoclonal mouse anti-6xHis/V5 antibody from Invitrogen diluted 1:5,000 in 
PBS/BSA at 4°C overnight. Each well was washed 4 times with 250μl PBS-Tween, 1 minute per 
wash. Wells were dried and incubated with 200μl of goat anti-mouse HRP-conjugated antibody 
(Jackson ImmunoResearch) diluted 1:20,000 in PBS/BSA for 1 hour at room temperature with 
nutation. Each well was washed 4 times with 250μl PBS-Tween, 1 minute per wash. Wells were 
dried and 200μl of TMB substrate were added to each well. Color development was monitored in 
a microplate reader and absorbance signals were recorded at 655nm using Wallac software.  
Alkaline Phosphatase Activity Quantification 
Alkaline phosphatase (AP) is an enzyme that removes a phosphate group from its 
substrate, para-nitrophenyl phosphate (PNPP), thus producing para-nitrophenol (PNP) which has 
a bright yellow color with absorbance measurable at 405nm wavelength. 100μl of anti-
digoxigenin AP-conjugated secondary antibody from Roche at 5mU/ml, 15mU/ml, and 30mU/ml 
in PBS/BSA, and 100μl of pUAST sdEGFR – AP protein supernatant at 1:5, 1:10, 1:20, 1:40, 
1:100, 1:200, 1:400, and 1:800 in PBS/BSA were added into the wells of a 96-well plate. 200μl 
of 1mM PNPP in 0.2M Tris, pH 8.0 were added to each well and incubated for 1hour at room 
temperature. Absorbance signals were recorded at 405nm using a microplate reader and Wallac 
software.  
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ELISA Assay of LIG and ErbB Protein Interactions 
A schematic picture of the ELISA interaction assay is presented in Figure 12. 200μl of 
pUAST sAmigo 1 – 6xHis/V5, pUAST sAmigo 2 – 6xHis/V5, pUAST sAmigo 3 – 6xHis/V5, 
pUAST sKek 1 – 6xHis/V5, pUAST sKek 2 – 6xHis/V5, and negative control supernatant 1:10 
dilution in PBS/BSA were added to the wells of a 96-well Qiagen Ni-NTA HisSorb Plate and 
incubated for 2 hours at room temperature with nutation. Each well was washed 4 times with 
250μl PBS-Tween, 1 minute per wash. Wells were dried and each was incubated at 4°C 
overnight with 200μl of pUAST sdEGFR – AP, pUAST sErbB1 – AP, pUAST sErbB2 – AP, 
pUAST sErbB3 – AP, or pUAST sErbB4 – AP diluted 1:10 in PBS/BSA. On the next day, each 
well was washed 4 times with 250μl PBS-Tween, 1 minute per wash. Wells were dried and 
200μl of 1mM PNPP in 0.2M Tris, pH 8.0 were added to each one, followed by an 1-hour 
incubation at room temperature. Absorbance signals were recorded at 405nm using a microplate 
reader and Wallac software.  
 
Figure 12: ELISA assay mechanism for detection of interactions between 6xHis/V5-tagged LIG 
proteins and AP-tagged ErbB proteins.  
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RESULTS 
Secreted Constructs of LIG Genes 
The extracellular regions of Amigo 1, Amigo 3, Lingo 1, and LRIG 1 were PCR-
amplified and inserted into pDONR 221; a BR reaction was also performed with a verified 
pUAST sAmigo 2 – 6xHis/V5 expression clone. The BP reaction products were successfully 
transformed in E.coli, cultured, and miniprepped, resulting in the following entry clones: pENTR 
sAmigo 1, pENTR sAmigo 2, pENTR sAmigo 3, pENTR sLingo 1, and pENTR sLRIG 1. 
pENTR sAmigo 1, pENTR sAmigo 2, and pENTR sAmigo 3 were sequence-verified and a 
segment of the sequenced pENTR sAmigo 1 clone is presented in Figure 13.  
 
Figure 13: A section of the sequenced pENTR sAmigo 1 construct.  
 
The generated pENTR clones were used to perform LR reactions with 6xHis/V5-, GFP-, 
and AP-containing pUAST vectors. The LR reaction products were successfully transformed in 
E.coli, cultured, and miniprepped, resulting in the following entry clones: pUAST sAmigo 1 – 
GFP, pUAST sAmigo 1 – AP, pUAST sAmigo 2 – GFP, pUAST sAmigo 2 – AP, pUAST 
sAmigo 3 – AP, pUAST sLingo 1 – 6xHis/V5, and pUAST sLRIG 1 – 6xHis/V5. A list of the 
produced pUAST constructs with their corresponding DNA concentrations is included in Table 
1. pUAST 6xHis/V5 expression clones with sAmigo 1, sAmigo 2, sAmigo 3, sKek 1, and sKek 2 
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pUAST 
sAMIGO1- 
6xHis/ 
V5 
pUAST 
sAMIGO2- 
6xHis/ 
V5 
pUAST 
sKek2- 
6xHis/ 
V5 
pUAST 
sKek1- 
6xHis/ 
V5 
pUAST 
sAMIGO3- 
6xHis/ 
V5 
S3 cell 
super-
natant 
had been previously generated in the Duffy lab, so the newly generated GFP- and AP-tagged 
expression clones are to allow for alternative detection mechanisms in an ELISA assay.  
Table 1: Generated expression clones of secreted LIG proteins.  
Construct Concentration (ng/μl) 
pUAST sAmigo 1 – GFP 408 
pUAST sAmigo 1 – AP 142 
pUAST sAmigo 2 – GFP 435 
pUAST sAmigo 2 – AP 307 
pUAST sAmigo 3 – AP 334 
pUAST sLingo 1 – 6xHis/V5 255 
pUAST sLRIG 1 – 6xHis/V5 288 
 
LIG Protein Expression and Detection through Western blot 
pUAST sAmigo 1 – 6xHis/V5, pUAST sAmigo 2 – 6xHis/V5, pUAST sAmigo 3 – 
6xHis/V5, pUAST sKek 1 – 6xHis/V5, pUAST sKek 2 – 6xHis/V5, pUAST sLingo 1 – 
6xHis/V5, and pUAST sLRIG 1 – 6xHis/V5 were co-transfected in S3 Drosophila cells using 
the UAS/GAL4 system. The expression clones included only the extracellular regions of the LIG 
genes, so the proteins were isolated by collecting and sterilizing the cell supernatants. The 
resulting protein supernatants and a negative control supernatant sample were run on SDS-PAGE 
gels. Figure 14 presents a picture of the performed Western blots.  
 
 
 
 
Figure 14: Western blots of secreted LIG protein supernatants.  
10-second film exposure 4-minute film exposure
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The Western blots revealed no degradation products for any of the LIG protein 
supernatants. All proteins ran at approximately the correct sizes, indicating full-size expression 
of the transfected constructs. A comparison between sequence-derived theoretical molecular 
weight and detected molecular weight values are listed in Table 2.  
 
Table 2: Theoretical and Western blot-detected molecular weight values of secreted LIG 
proteins.  
Protein Construct Theoretical Molecular Weight 
(kDa) 
Approximate Detected Molecular 
Weight (kDa) 
pUAST sAmigo 1 – 6xHis/V5 44.3 43.5 
pUAST sAmigo 2 – 6xHis/V5 47.3 44.5 
pUAST sAmigo 3 – 6xHis/V5 45.6 44.0 
pUAST sKek 1 – 6xHis/V5 52.3 52.0 
pUAST sKek 2 – 6xHis/V5 45.4 46.0 
 
LIG Protein Quantification 
An ELISA assay was performed to evaluate the levels of 6xHis/V5-tagged LIG proteins 
sufficient to occupy all Ni
2+
 binding sites in a well of a Qiagen Ni-NTA HisSorb Plate. The 
6xHis tag of each protein binds to the Ni
2+
- conjugated to each well, while the antibodies probe 
for the V5 part of the tag, enabling the detection and determination of protein concentration. 
pUAST sAmigo 1 – 6xHis/V5, pUAST sAmigo 2 – 6xHis/V5, pUAST sAmigo 3 – 6xHis/V5, 
pUAST sKek 1 – 6xHis/V5, pUAST sKek 2 – 6xHis/V5, pUAST sLingo 1 – 6xHis/V5, and 
pUAST sLRIG 1 – 6xHis/V5, as well as a negative control supernatant sample were assayed at a 
range of dilutions between 1:10 and 1:400. The resulting absorbance signals were plotted and 
yielded Ni
2+
 saturation curves for each protein, as presented in Figure 15.  
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Figure 15: ELISA quantification plots of secreted LIG proteins.  
 
pUAST sAmigo 1 – 6xHis/V5 and pUAST sAmigo 3 – 6xHis/V5, followed by pUAST 
sAmigo 2 – 6xHis/V5 exhibited the greatest increase in absorbance associated with higher 
protein concentrations. At the highest concentration of 0.1, the absorbance signals of pUAST 
sAmigo 1 – 6xHis/V5 and pUAST sAmigo 3 – 6xHis/V5 were approximately 3.5 times higher 
than the supernatant’s signal, while the absorbance of pUAST sAmigo 2 – 6xHis/V5 was 2.6 
times higher. pUAST sLingo 1 – 6xHis/V5 and pUAST sKek 1 – 6xHis/V5 had relatively low 
absorbance results, only 1.4 and 1.2 times higher than that of the supernatant, respectively. 
pUAST sKek 2 – 6xHis/V5 and pUAST sLRIG 1 – 6xHis/V5 had virtually the same absorbance 
signals as the negative control supernatant. It was determined that a dilution of 1:10 was suitable 
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for the purposes of an ELISA assay, since the absorbance curves of most proteins reached a 
plateau region at that concentration, indicating saturation of the Nickel binding sites of the 
Qiagen Ni-NTA HisSorb Plate wells.  
 
Quantification of Alkaline Phosphatase Activity 
pUAST sdEGFR – AP protein supernatant was produced by A. Putnam, a graduate 
student in the Duffy lab, following the same UAS/GAL4 expression system protocol in S3 
Drosophila cells.  An assay with PNPP substrate was performed with the protein and an AP-
conjugated antibody (positive control) to assess the alkaline phosphatase activity of the 
expressed construct. The antibody dilutions (5mU/ml, 15mU/ml, and 30mU/ml) and the pUAST 
sdEGFR – AP dilutions ranging between 0.2 and 0.00125 were incubated with PNPP for the 
same amount of time. The absorbance signals of the antibody dilutions at 405nm were plotted to 
produce a standard curve of PNP product conversion as a function of AP activity levels. The 
resulting standard curve is displayed in Figure 16.  
 
Figure 16: Standard curve of produced PNP absorbance as a function of alkaline phosphatase 
activity levels.  
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The absorbance signals of the pUAST sdEGFR – AP samples were plotted against their 
dilution factors, as presented in Figure 17. In the lowest concentration range between 0.05 and 
0.00125, increase in protein amount did not produce a steady growth in absorbance. The highest 
pUAST sdEGFR – AP concentration level, 0.2, produced an absorbance signal 1.6 times lower 
than that 5mU/ml AP-conjugated antibody sample. Through the trendline equation of the AP 
activity standard curve, it was calculated that the total AP activity of the undiluted pUAST 
sdEGFR – AP protein was 31.9mU/ml.  
 
Figure 17: PNP absorbance signals of pUAST sdEGFR – AP samples at a range of 
concentrations.  
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ELISA Interaction of LIG and ErbB Proteins 
pUAST sdEGFR – AP, pUAST sErbB1 – AP, pUAST sErbB2 – AP, pUAST sErbB3 – 
AP, and pUAST sErbB4 – AP protein supernatants were obtained from A. Putnam – a graduate 
student in the Duffy lab. All AP-tagged constructs had been produced according to the 
UAS/GAL4 expression system protocol. All 6xHis/V5-tagged and AP-tagged proteins had been 
expressed in the same manner and pUAST sdEGFR – AP exhibited alkaline phosphatase 
activity. pUAST sAmigo 1 - 6xHis/V5, pUAST sAmigo 2 - 6xHis/V5 and pUAST sAmigo 3 - 
6xHis/V5 demonstrated binding capacity in the ELISA quantification assay (Figure 15); pUAST 
sKek 1 - 6xHis/V5 and pUAST sKek 2 - 6xHis/V5 did not exhibit high absorbance signals in the 
same ELISA assay, but were detected at their expected sizes in a Western blot (Figure 14). 
Therefore, an ELISA assay was performed to test for interactions between pairs of each of the 
mentioned 6xHis/V5-tagged and AP-tagged proteins, as well as negative control supernatant. 0.1 
concentrations of each protein were used in the assay, since samples of that concentration had 
exhibited good binding to Qiagen Ni-NTA HisSorb Plate wells (Figure 15).  
In the assay, LIG/ErbB interactions are manifested through high absorbance at 405nm 
resulting from alkaline phosphatase-induced PNPP conversion to PNP (Figure 14). Absorbance 
signals from all interaction wells were recorded at 405nm and plotted in a graph displayed in 
Figure 18. No significant signals were detected between any of the LIG/ErbB pairs, including the 
positive control pUAST sKek 1 - 6xHis/V5 and pUAST sdEGFR – AP pair that has been 
experimentally shown to interact in multiple studies.  
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Figure 18: Absorbance results of the ELISA interaction assay between 6xHis/V5-tagged LIG 
proteins and AP-tagged ErbB proteins.  
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DISCUSSION 
This work produced pENTR clones of secreted versions of Amigo 1, Amigo 2, Amigo 3, 
Lingo 1, and LRIG 1 through the Gateway cloning system. pUAST-GFP clones  of sAmigo 1 
and sAmigo, pUAST-AP clones of sAmigo 1, sAmigo 2, and sAmigo 3, as well as pUAST-
6xHis/V5 clones of sLingo 1 and sLRIG 1 were also generated. Through the UAS/GAL4 system 
in Drosophila, 6xHis/V5-tagged LIG secreted constructs were fully expressed to proteins with 
Ni
2+
 -binding capability. The LIG protein concentration sufficient for detection in an ELISA 
assay with Nickel plate wells was determined. The alkaline phosphatase activity of a pUAST 
sdEGFR – AP protein sample was demonstrated and quantified. A high-throughput ELISA assay 
was performed with pairs of secreted 6xHis/V5-tagged LIG and AP-tagged ErbB proteins, but no 
signals were detected even between the positive control pUAST sKek 1 – 6xHis/V5 and pUAST 
sdEGFR – AP pair.  
The lack of signals through the LIG/ErbB ELISA assay could be due to a few possible 
reasons. The AP-tagged dEGFR and ErbBs may not have been expressed to fully functional 
proteins. pUAST sdEGFR – AP did exhibit alkaline phosphatase activity, however because a 
Western Blot has not yet been performed it is unknown if the fusion protein is of the correct size 
and stable. In addition, it’s possible that the AP-tagged dEGFR and ErbBs may have had low 
concentrations and the determined amount alkaline phosphatase activity was insufficient for 
proper detection in the ELISA interaction assay. Another concern is that the alkaline phosphatase 
tag could cause steric hindrance of LIG-ErbB interactions, thus interfering with the formation of 
binding between the protein molecules.  
Interestingly the pUAST sKek 1 – 6xHis/V5 and pUAST sKek 1 – 6xHis/V5 proteins 
were fully expressed based on Western blot analysis, but did not produce high absorbance in the 
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ELISA quantification assay (Figure 15).  One possible explanation is that the molecules of each 
protein bind homophilically, sterically hindering binding to the Ni
2+
 in the plate’s wells. In that 
case, the positive control sKek 1 – sdEGFR interaction may not have resulted in a detectable 
signal due to insufficient pUAST sKek 1 – 6xHis/V5 molecules bound to the well. However, 
sAmigo 1, sAmigo 2, and sAmigo 3 did have good Nickel binding capacities, so the current 
ELISA interaction results might indicate that no natural interactions occur between these LIG 
proteins and the tested ErbB proteins.  
Further work should determine the level of chromogenic signal emitted at saturating AP 
concentrations. This can be achieved by generating an AP-6xHis/V5 construct. The 6xHis/V5 tag 
will occupy all Ni-Nta binding sites, while the AP tag would allow for quantification of the 
signal derived from saturating levels of AP. New co-transfections of the AP-tagged ErbB 
constructs may be performed to yield protein supernatants of higher alkaline phosphatase 
activity. The use of such samples in another interaction ELISA can reveal whether low AP 
activity of tagged ErbB proteins disabled notable detection, or the AP tag disturbs the interaction 
complex sterically.  Should the latter be confirmed, cloning and expression of ErbB constructs 
with other tags may allow for detection of interactions in a high-throughput ELISA. Finally, the 
pUAST sKek 1 – 6xHis/V5 and pUAST sKek 2 – 6xHis/V5 protein supernatants removed from 
Nickel plate wells post-incubation may be assessed by Western blot analysis to determine 
whether sKek 1 and sKek 2 molecules bind homophilically in solution, which prevents them 
from sticking to the Nickel-coated wells.  
Judging from the ELISA assay results, Nickel-coated wells allow binding of 6xHis/V5-
tagged LIG proteins. Alternatively, the generated AP-tagged LIG constructs can be expressed 
and used for attachment to anti-AP antibody-coated wells. Once ErbB proteins of sufficient 
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concentration and non-interfering tags are provided, a high-throughput ELISA can deliver 
definitive information about the presence or absence of robust LIG-ErbB interactions. The 
development of such a high throughput assay for protein-protein interactions would provide a 
significant step towards identifying LIG binding partners and understanding the specific 
functions that LIG proteins serve in vivo.  
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